<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.96114</article-id><article-id pub-id-type="publisher-id">ACM-30771</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190600000_46387937.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  比较替莫唑胺联合阿帕替尼与替莫唑胺联合贝伐珠单抗治疗复发或进展性脑胶质瘤得疗效分析
  Comparison of the Efficacy of Temozolomide Combined with Apatinib and Temozolomide Combined with Bevacizumab in the Treatment of Recurrent or Progressive Glioma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>薛</surname><given-names>楠楠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>想想</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>俊启</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>顾</surname><given-names>浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>鑫</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>松</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>樊</surname><given-names>锐太</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>郑州大学第一附属医院放疗科，河南 郑州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>06</day><month>06</month><year>2019</year></pub-date><volume>09</volume><issue>06</issue><fpage>744</fpage><lpage>750</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨比较替莫唑胺分别联合阿帕替尼和贝伐珠单抗治疗复发或进展性脑胶质瘤的疗效及安全性。方法：选取2012-01-01到2017-12-31间我院放疗科收治的99例术后复发性脑胶质瘤患者为回顾性研究对象，其中43例采用TMZ + APT方案，56例采用TMZ + BEV方案，在治疗后第8周、第20周和第25周进行疗效评价以及不良反应评估，并随访两组患者的总生存率(OS)。结果：TMZ + APT组患者近期及远期疗效(OS)均优于TMZ + BEV (P &lt; 0.05)，两组患者最主要的不良反应是骨髓抑制，TMZ + APT组患者骨髓移植主要发生在3级以上，而TMZ+BEV组患者主要发生在1~2级，两组之间比较差异具有统计学意义(P &lt; 0.05)；高血压主要发生在TMZ + APT组，TMZ + BEV组相对较少，差异具有统计学意义(P &lt; 0.05)；出血以及血栓主要发生在TMZ + BEV组，而TMZ + APT组相对较少，差异无统计学意义。结论：不论近期疗效还是远期疗效，阿帕替尼联合替莫唑胺治疗复发性脑胶质瘤均优于替莫唑胺联合贝伐珠单抗方案，且不良反应级别较低，具有可控性。
    Objective: To compare the efficacy and safety of temozolomide combined with apatinib and te-mozolomide combined with bevacizumab in the treatment of recurrent or progressive glioma. Methods: A total of 99 patients with recurrent glioma in our hospital were retrospectively selected. Among them, 43 patients underwent TMZ + APT and 56 patients underwent TMZ + BEV. Efficacy and adverse effects were assessed at 8 weeks, 20 weeks, and 25 weeks after treatment, and the overall survival (OS) of the two groups was followed. Results: The short-term outcomes and overall survival (OS) of the TMZ + APT group were better than the TMZ + BEV group (P &lt; 0.05). The most significant adverse reaction was myelosuppression in the two groups. The bone marrow transplantation in the TMZ + APT group occurred mainly above grade 3; the patients in the TMZ + BEV group mainly occurred in grade 1~2. The difference between the two groups was statistically significant (P &lt; 0.05). The hypertension mainly occurred in the TMZ + APT group, and the TMZ + BEV group was relatively less. The difference was statistically significant (P &lt; 0.05); bleeding and thrombosis occurred mainly in the TMZ + BEV group, while the TMZ + APT group was relatively less, but the difference was not statistically significant. Conclusion: Regardless of short-term efficacy or long-term efficacy, temozolomide combined with apatinib is superior to temozolomide combined with bevacizumab in the treatment of recurrent or progressive glioma, and the level of adverse reactions is low and controllable. 
  
 
</p></abstract><kwd-group><kwd>复发性或进展性脑胶质瘤，贝伐珠单抗，替莫唑胺，阿帕替尼, Recurrent or Progressive Malignant Glioma</kwd><kwd> Bevacizumab</kwd><kwd> Temozolomide</kwd><kwd> Apatinib</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>比较替莫唑胺联合阿帕替尼与替莫唑胺联合 贝伐珠单抗治疗复发或进展性脑胶质瘤得 疗效分析<sup> </sup></title><p>薛楠楠，杨想想，刘俊启，顾浩，王鑫，张松，樊锐太<sup>*</sup></p><p>郑州大学第一附属医院放疗科，河南 郑州</p><disp-formula id="hanspub.30771-formula35"><graphic xlink:href="//html.hanspub.org/file/4-1570944x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年5月20日；录用日期：2019年6月6日；发布日期：2019年6月14日</p><disp-formula id="hanspub.30771-formula36"><graphic xlink:href="//html.hanspub.org/file/4-1570944x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨比较替莫唑胺分别联合阿帕替尼和贝伐珠单抗治疗复发或进展性脑胶质瘤的疗效及安全性。方法：选取2012-01-01到2017-12-31间我院放疗科收治的99例术后复发性脑胶质瘤患者为回顾性研究对象，其中43例采用TMZ + APT方案，56例采用TMZ + BEV方案，在治疗后第8周、第20周和第25周进行疗效评价以及不良反应评估，并随访两组患者的总生存率(OS)。结果：TMZ + APT组患者近期及远期疗效(OS)均优于TMZ + BEV (P &lt; 0.05)，两组患者最主要的不良反应是骨髓抑制，TMZ + APT组患者骨髓移植主要发生在3级以上，而TMZ+BEV组患者主要发生在1~2级，两组之间比较差异具有统计学意义(P &lt; 0.05)；高血压主要发生在TMZ + APT组，TMZ + BEV组相对较少，差异具有统计学意义(P &lt; 0.05)；出血以及血栓主要发生在TMZ + BEV组，而TMZ + APT组相对较少，差异无统计学意义。结论：不论近期疗效还是远期疗效，阿帕替尼联合替莫唑胺治疗复发性脑胶质瘤均优于替莫唑胺联合贝伐珠单抗方案，且不良反应级别较低，具有可控性。</p><p>关键词 :复发性或进展性脑胶质瘤，贝伐珠单抗，替莫唑胺，阿帕替尼</p><disp-formula id="hanspub.30771-formula37"><graphic xlink:href="//html.hanspub.org/file/4-1570944x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1570944x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1570944x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>恶性脑胶质瘤是成人中枢神经系统肿瘤最常见的原发性恶性肿瘤，该疾病的发病率在颅内和中枢神经系统肿瘤疾病中占80% [<xref ref-type="bibr" rid="hanspub.30771-ref1">1</xref>] 。目前，恶性脑胶质母细胞瘤的标准治疗方案仍然是手术切除，术后辅以放化疗，然而，由于此病侵袭强、恶性程度高，其复发率仍然很高。复发的恶性脑胶质瘤较之前更可以进展到更具有侵略性的状态，并且几乎没有治疗选择。Nieder C等人的研究表明复发的恶性胶质瘤患者存活的时间为6~8个月 [<xref ref-type="bibr" rid="hanspub.30771-ref2">2</xref>] ，第二次进展的患者中位生存期更短，仅为14周 [<xref ref-type="bibr" rid="hanspub.30771-ref3">3</xref>] ，对于复发或进展性质瘤治疗选择目前没有标准的治疗策略，主要有再次手术、系统放化疗以及对症支持治疗。在加拿大，替莫唑胺被推荐可用作复发性或进展性胶质瘤的治疗 [<xref ref-type="bibr" rid="hanspub.30771-ref4">4</xref>] 。替莫唑胺为咪唑合并四嗪类具有抗肿瘤活性的烷化剂，进体循环后迅速转化为细胞毒性产物MTIC，MTIC通过甲基化加成物的错配修复，发挥细胞毒作用。替莫唑胺的活化形式容易穿过血脑屏障，因此用于治疗原发或者继发性颅内肿瘤。但替莫唑胺治疗复发性或进展性胶质瘤的总体缓解率仍不令人满意。有研究表明阿帕替尼联合替莫唑胺治疗复发性脑胶质瘤的临床疗效确切，与单用替莫唑胺相比，阿帕替尼联合替莫唑胺能够提高患者的近期疗效 [<xref ref-type="bibr" rid="hanspub.30771-ref5">5</xref>] 。也有报道指出贝伐珠单抗联合替莫唑胺能够提高患者的治疗效果，且安全性较高，不良反应较少 [<xref ref-type="bibr" rid="hanspub.30771-ref6">6</xref>] 。本研究主要目的是回顾性分析两种化疗方案对复发性胶质瘤患者的临床疗效以及生存状况差异，为临床治疗复发性或进展性脑胶质瘤提供更好的临床依据。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>选取2012-01到2017-12间我院放疗科收治的术后复发性脑胶质瘤患者为回顾性研究对象，入选标准：手术后病理证实为恶性脑胶质瘤并且影像学证实复发或进展的患者；接受阿帕替尼联合替莫唑胺或贝伐珠单抗联合替莫唑胺方案化疗；KPS评分 ≥ 70分，预计生存期 &gt; 4个月，无严重的心肺、肝肾功障碍；临床资料完整，未接受其他放化疗治疗；共有99例复发性胶质瘤患者符合标准，其中阿帕联合替莫有43例，男性27例，女性16例，年龄24~73岁，中位年龄61岁。贝伐联合替莫有56例，男性30例，女性16例，年龄27~65岁，中位年龄63岁。两组患者的基本特征如表1所示。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Character of basic data between the two groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >TMZ + APT (n = 43) N</th><th align="center" valign="middle" >TMZ + BEV (n = 56) N</th><th align="center" valign="middle" >c<sup>2</sup>值</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中位年龄</td><td align="center" valign="middle" >61岁</td><td align="center" valign="middle" >63岁</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;50</td><td align="center" valign="middle" >5 (11.63%)</td><td align="center" valign="middle" >9 (16.07%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.575</td></tr><tr><td align="center" valign="middle" >≥50</td><td align="center" valign="middle" >38 (88.4%)</td><td align="center" valign="middle" >47 (83.93%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >20 (46.51%)</td><td align="center" valign="middle" >31 (55.36%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.422</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >23 (53.49%)</td><td align="center" valign="middle" >25 (44.64%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >脑部病变的数量</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >19 (44.19%)</td><td align="center" valign="middle" >34 (60.71%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.110</td></tr><tr><td align="center" valign="middle" >&gt;1</td><td align="center" valign="middle" >24 (55.81%)</td><td align="center" valign="middle" >22 (39.29%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >术后KPS评分</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >70~80</td><td align="center" valign="middle" >10 (23.26%)</td><td align="center" valign="middle" >20 (35.71%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.195</td></tr><tr><td align="center" valign="middle" >90~100</td><td align="center" valign="middle" >33 (76.74%)</td><td align="center" valign="middle" >36 (64.29%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤等级</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" >18 (41.86%)</td><td align="center" valign="middle" >26 (46.43%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.687</td></tr><tr><td align="center" valign="middle" >IV</td><td align="center" valign="middle" >25 (58.14%)</td><td align="center" valign="middle" >30 (53.57%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肢体活动障碍</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >19 (44.19%)</td><td align="center" valign="middle" >24 (42.86%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >24 (55.81%)</td><td align="center" valign="middle" >32 (57.14%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >癫痫</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >32 (74.42%)</td><td align="center" valign="middle" >33 (58.93%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.136</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >11 (25.58%)</td><td align="center" valign="middle" >23 (41.07%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 两组患者的基本资料比较</p></sec><sec id="s4_2"><title>2.2. 治疗方案</title><p>替莫唑胺采用剂量密度方案：一日1次，每次剂量100 mg/m<sup>2</sup>连续服用21天，停7天为一个周期，服用至病情进展。TMZ + APT组在替莫唑胺治疗的基础上加用阿帕替尼口服500 mg，每日1次。同样，TMZ + BEV组在替莫唑胺治疗的基础上在第1、15天加用贝伐珠单抗，剂量为10 mg/Kg。</p></sec><sec id="s4_3"><title>2.3. 疗效评价及不良反应</title><p>疗效评价在治疗后8周进行近期疗效评价。根据WHO对肿瘤疗效评价标准分为：完全缓解(CR)，部分缓解(PR)，病情稳定(SD)，病情进展(PD) [<xref ref-type="bibr" rid="hanspub.30771-ref7">7</xref>] 。所有患者均定期检测不良反应，按WHO标准进行评定。</p></sec><sec id="s4_4"><title>2.4. 统计学方法</title><p>对于分类变量资料我们采用χ<sup>2</sup>检验，等级资料采用spearman相关系数。使用Kaplan-Meier方法评估总生存期(OS)，log-rank检验比较两组间OS差异。差异显著性定义为P &lt; 0.05。所有统计分析均使用SPSS 21.0版。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 临床疗效比较</title><p>两组患者在治疗2月后进行了疗效评价。TMZ + APT组：CR 11例(25.58%)，PR 12例(27.91%)，SD 9例(20.93%)，PD 2例(4.65%)；TMZ + BEV组：CR 5例(8.93%)，PR 22例(39.29%)，SD 20例(35.71%)，PD 9例(16.07%)，采用χ<sup>2</sup>检验统计分析，结果表明：两组患者疾病近期疗效比较，结果发现两组之间差异具有统计学意义(P &lt; 0.05，见表2)。提示阿帕替尼联合替莫唑胺治疗脑胶质瘤术后复发的患者近期疗效优于贝伐珠单抗联合替莫唑胺治疗。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical efficacy of two groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >完全缓解(CR)</th><th align="center" valign="middle" >部分缓解(PR)</th><th align="center" valign="middle" >病情稳定(SD)</th><th align="center" valign="middle" >病情进展(PD)</th><th align="center" valign="middle" >c<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >TMZ + APT (n = 43)</td><td align="center" valign="middle" >11 (25.58%)</td><td align="center" valign="middle" >12 (27.91%)</td><td align="center" valign="middle" >9 (20.93%)</td><td align="center" valign="middle" >2 (4.65%)</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.036</td></tr><tr><td align="center" valign="middle" >TMZ + BEV (n = 56)</td><td align="center" valign="middle" >5 (8.93%)</td><td align="center" valign="middle" >22 (39.29%)</td><td align="center" valign="middle" >20 (35.71%)</td><td align="center" valign="middle" >9 (16.07%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 两组患者临床疗效比较</p></sec><sec id="s5_2"><title>3.2. 不良反应发生情况比较</title><p>两组患者最主要的不良反应是骨髓抑制，TMZ + APT组患者骨髓移植主要发生在3级以上，而TMZ + BEV组患者主要发生在1~2级，两组之间比较差异具有统计学意义(P &lt; 0.05)；高血压主要发生在TMZ + APT组，TMZ + BEV组相对较少，差异具有统计学意义(P &lt; 0.05)，与口服阿帕替尼的副作用有关，给予降压药后好转；出血以及血栓主要发生在TMZ + BEV组，而TMZ + APT组相对较少，与贝伐珠单抗副作用有关。两组之间比较，差异无统计学意义。见表3。</p></sec><sec id="s5_3"><title>3.3. 远期疗效</title><p>对比两组患者的总生存：TMZ + BEV组的中位生存期(OS)为424天，TMZ + APT组的中位生存期(OS)为639天。并进行生存分析比较两组间的OS，其差异具有统计学意义(P = 0.048，见图1)，即阿帕替尼联合替莫唑胺治疗脑胶质瘤术后复发的患者远期疗效优于贝伐珠单抗联合替莫唑胺治疗。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Adverse events of two groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >不良反应</th><th align="center" valign="middle"  colspan="2"  >TMZ + APT (n = 43)</th><th align="center" valign="middle"  colspan="2"  >TMZ + BEV (n = 56)</th><th align="center" valign="middle"  rowspan="2"  >c<sup>2</sup>值</th><th align="center" valign="middle"  rowspan="2"  >P</th></tr></thead><tr><td align="center" valign="middle" >1~2级</td><td align="center" valign="middle" >3~4级</td><td align="center" valign="middle" >1~2级</td><td align="center" valign="middle" >3~4级</td></tr><tr><td align="center" valign="middle" >骨髓抑制</td><td align="center" valign="middle" >7 (16.28%)</td><td align="center" valign="middle" >10 (23.26%)</td><td align="center" valign="middle" >15 (26.79%)</td><td align="center" valign="middle" >4 (7.14%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.039</td></tr><tr><td align="center" valign="middle" >恶心呕吐</td><td align="center" valign="middle" >15 (34.86%)</td><td align="center" valign="middle" >7 (16.28%)</td><td align="center" valign="middle" >18 (32.14%)</td><td align="center" valign="middle" >5 (8.93%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.514</td></tr><tr><td align="center" valign="middle" >乏力</td><td align="center" valign="middle" >18 (41.86%)</td><td align="center" valign="middle" >5 (11.63%)</td><td align="center" valign="middle" >15 (26.79%)</td><td align="center" valign="middle" >10 (17.86%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.221</td></tr><tr><td align="center" valign="middle" >高血压</td><td align="center" valign="middle" >15 (34.88%)</td><td align="center" valign="middle" >4 (9.30%)</td><td align="center" valign="middle" >3 (5.36%)</td><td align="center" valign="middle" >6 (10.71%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.035</td></tr><tr><td align="center" valign="middle" >转氨酶异常</td><td align="center" valign="middle" >5 (11.63%)</td><td align="center" valign="middle" >2 (4.65%)</td><td align="center" valign="middle" >1 (1.79%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >出血</td><td align="center" valign="middle" >2 (4.65%)</td><td align="center" valign="middle" >1 (2.33%)</td><td align="center" valign="middle" >24 (42.86%)</td><td align="center" valign="middle" >4 (7.14%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.422</td></tr><tr><td align="center" valign="middle" >蛋白尿</td><td align="center" valign="middle" >13 (30.23%)</td><td align="center" valign="middle" >7 (16.28%)</td><td align="center" valign="middle" >9 (16.71%)</td><td align="center" valign="middle" >12 (21.43%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.215</td></tr><tr><td align="center" valign="middle" >血栓</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >3 (5.36%)</td><td align="center" valign="middle" >2 (3.57%)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>表3. 两组患者不良反应比较</p><p>图1. 两组患者总生存率比较</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>恶性脑胶质瘤恶性程度高，具有高度侵袭性，尽管以手术为主加术后放化疗的综合治疗取得了重大进展，但恶性胶质瘤患者容易复发，其预后仍然很差，根据中国胶质瘤基因组图谱(CGGA)统计，初步诊断后平均存活时间为14.4个月 [<xref ref-type="bibr" rid="hanspub.30771-ref8">8</xref>] 。目前多项研究发现复发或进展胶质瘤对单药替莫唑胺的反应不佳，因此，需要探究用于神经胶质瘤治疗的新型组合策略。</p><p>胶质瘤本质上是血管瘤，并且富含血管内皮生长因子(VEGF)，胶质瘤的生长、进展与肿瘤血管生成的关系密切。贝伐珠单抗作为抑制血管内皮生长因子的一种单克隆抗体，已被用于治疗神经胶质瘤患者，然而，它用于治疗神经胶质瘤需要考虑一些独特因素，例如其与出血等副反应的关系。有研究表明与安慰剂组相比，单用北伐珠单抗组出现更严重的不良反应事件 [<xref ref-type="bibr" rid="hanspub.30771-ref9">9</xref>] ，但是国内也有报道，贝伐珠单抗联合化疗后出现高血压以及出血等不良反应并不常见 [<xref ref-type="bibr" rid="hanspub.30771-ref10">10</xref>] 。本研究证实与TMZ + APT组相比，TMZ + BEV组患者更容易出现出血(26例 vs 2例)、血栓(5例 vs 0例)等不良反应。</p><p>阿帕替尼是一种口服给药的第二代VEGF抑制剂，阿帕替尼可预防VEGF诱导的VEGFR2磷酸化和随后的下游信号传导，从而阻止VEGF的生物学作用。临床研究表明，阿帕替尼在不同类型的恶性实体肿瘤患者中具有抗肿瘤活性。但阿帕替尼对于脑胶质瘤的治疗效果的临床报道仍然很少。研究表明阿帕替尼能够使细胞增殖减少，集落形成，侵袭和迁移以及细胞凋亡增加，从而发挥抗胶质瘤肿瘤细胞活性并且增强替莫唑胺在胶质瘤细胞中的作用。Xiaodongiang等人的研究表明阿帕替尼联合伊利替康在治疗高级别的脑胶质瘤中具有客观的疗效，且其不良反应具有耐受性和可控性 [<xref ref-type="bibr" rid="hanspub.30771-ref11">11</xref>] 。本研究的结果与此报道一致，TMZ + APT组患者的不良反应包括骨髓抑制，高血压、胃肠道反应等，大多集中在1~2级，给予对症处理后，症状好转。且其治疗复发性脑胶质瘤的疗效较好，在近期疗效及远期疗效方面均优于TMZ + BEV组。</p><p>先前的研究表明，不论替莫唑胺联合阿帕替尼方案还是替莫唑胺联合贝伐珠单抗方案治疗复发或者进展胶质瘤患者均优于替莫唑胺单药治疗 [<xref ref-type="bibr" rid="hanspub.30771-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.30771-ref13">13</xref>] 。但仍缺少对于这两种方案之间比较的数据。我们的研究结果显示，TMZ + APT组患者近期疗效优于TMZ + BEV组，差异具有统计学意义(P = 0.036)。对两组数据进行生存分析结果显示，TMZ + APT组患者远期疗效同样优于TMZ + BEV组，差异具有统计学意义(P = 0.048)。我们的结果首次证明，替莫唑胺联合阿帕替尼的新辅助治疗方案在近期及远期疗效方面均优于替莫唑胺联合贝伐珠单抗方案。</p><p>本研究回顾性分析替莫唑胺分别联合贝伐珠单抗和阿帕替尼两种化疗方案对复发性胶质瘤患者的临床疗效以及生存状况差异，我们的初步研究结果不论近期疗效还是远期疗效，阿帕替尼联合替莫唑胺治疗复发性脑胶质瘤均优于替莫唑胺联合贝伐珠单抗方案，且不良反应级别较低，具有可控性。但本研究由于样本量较少，以及研究的时间跨度大等原因，仍需要前瞻性研究进一步确认本研究结果。</p></sec><sec id="s7"><title>基金项目</title><p>河南省高等学校重点科研项目(19A320036)。</p></sec><sec id="s8"><title>文章引用</title><p>薛楠楠,杨想想,刘俊启,顾 浩,王 鑫,张 松,樊锐太. 比较替莫唑胺联合阿帕替尼与替莫唑胺联合贝伐珠单抗治疗复发或进展性脑胶质瘤得疗效分析Comparison of the Efficacy of Temozolomide Combined with Apatinib and Temozolomide Combined with Bevacizumab in the Treatment of Recurrent or Progressive Glioma[J]. 临床医学进展, 2019, 09(06): 744-750. https://doi.org/10.12677/ACM.2019.96114</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30771-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Y., et al. (2017) A Proangiogenic Signaling Axis in Myeloid Cells Promotes Malignant Progression of Glioma. Journal of Clinical Investigation, 127, 1826-1838. &lt;br&gt;https://doi.org/10.1172/JCI86443</mixed-citation></ref><ref id="hanspub.30771-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Nieder, C., Grosu, A.L. and Molls, M. (2000) A Comparison of Treatment Results for Recurrent Malignant Gliomas. Cancer Treatment Reviews, 26, 397-409. &lt;br&gt;https://doi.org/10.1053/ctrv.2000.0191</mixed-citation></ref><ref id="hanspub.30771-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Huncharek, M. and Muscat, J. (1998) Treatment of Recurrent High Grade Astrocytoma: Results of a Systematic Review of 1,415 Patients. Anticancer Research, 18, 1303-1311.</mixed-citation></ref><ref id="hanspub.30771-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Easaw, J.C., et al. (2011) Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme. Current Oncology, 18, e126-e136. &lt;br&gt;https://doi.org/10.3747/co.v18i3.755</mixed-citation></ref><ref id="hanspub.30771-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">王保庆, 孙增先, 赵作银. 阿帕替尼联合替莫唑胺治疗脑胶质瘤术后复发患者的疗效观察[J]. 黑龙江医学, 2017, 41(11): 1096-1097.</mixed-citation></ref><ref id="hanspub.30771-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">王飞, 李春红. 贝伐珠单抗联合替莫唑胺治疗复发恶性脑胶质瘤的临床效果及安全性[J]. 中国医药, 2018, 13(10): 1510-1513.</mixed-citation></ref><ref id="hanspub.30771-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">王健. WHO标准与RECIST标准评价恶性肿瘤治疗效果的比较[J]. 中国基层医药, 2013, 20(5): 652-654.</mixed-citation></ref><ref id="hanspub.30771-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, T., et al. (2016) CGCG Clinical Practice Guidelines for the Management of Adult Diffuse Gliomas. Cancer Letters, 375, 263-273. &lt;br&gt;https://doi.org/10.1016/j.canlet.2016.01.024</mixed-citation></ref><ref id="hanspub.30771-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Saran, F., et al. (2016) Bevacizumab, Temozolomide, and Radiotherapy for Newly Diagnosed Glioblastoma: Comprehensive Safety Results during and after First-Line Therapy. Neuro-Oncology, 18, 991-1001. 
&lt;br&gt;https://doi.org/10.1093/neuonc/nov300</mixed-citation></ref><ref id="hanspub.30771-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">史芳. 贝伐珠单抗治疗恶性肿瘤的不良反应临床分析[J]. 医学理论与实践, 2017, 30(23): 3502-3503.</mixed-citation></ref><ref id="hanspub.30771-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., et al. (2017) A Pilot Clinical Study of Apatinib Plus Irinotecan in Patients with Recurrent High-Grade Glioma: Clinical Trial/Experimental Study. Medicine, 96, e9053. &lt;br&gt;https://doi.org/10.1097/MD.0000000000009053</mixed-citation></ref><ref id="hanspub.30771-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Balana, C., et al. (2016) Bevacizumab and Temozolomide versus Temozolomide Alone as Neoadjuvant Treatment in Unresected Glioblastoma: The GENOM 009 Randomized Phase II Trial. Journal of Neuro-Oncology, 127, 569-579. 
&lt;br&gt;https://doi.org/10.1007/s11060-016-2065-5</mixed-citation></ref><ref id="hanspub.30771-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wang, C., et al. (2018) Apatinib Suppresses Cell Growth and Metastasis and Promotes Antitumor Activity of Temozolomide in Glioma. Oncology Letters, 16, 5607-5614. &lt;br&gt;https://doi.org/10.3892/ol.2018.9355</mixed-citation></ref></ref-list></back></article>